DDX41 and hemolytic-uremic syndrome: Although several treatments based on anti‐Stx Abs have been developed and some of them are currently being assayed in clinical trials9, 21, the major drawback of these approaches is that they are applied when HUS is diagnosed and this is probably too late in relation to progression of the pathogenic cascade.